Regulatory News
Thursday, March 17, 2016
BRIEF-Dimension Therapeutics to submit investigational new drug application for DTX301
* Dimension Therapeutics receives positive opinion for
European orphan drug designation for DTX301 for treatment of
ornithine transcarbamylase (OTC) deficiency
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment